TY  - JOUR 
AU  - Laubach, Jacob P.
AU  - Moslehi, Javid J.
AU  - Francis, Sanjeev A.
AU  - San Miguel, Jesús F.
AU  - Sonneveld, Pieter
AU  - Orlowski, Robert Z.
AU  - Moreau, Philippe
AU  - Rosiñol, Laura
AU  - Faber, Edward A.
AU  - Voorhees, Peter
AU  - Mateos Manteca, María Victoria
AU  - Marquez, Loreta
AU  - Feng, Huaibao
AU  - Desai, Avinash
AU  - van de Velde, Helgi
AU  - Elliott, Jennifer
AU  - Shi, Hongliang
AU  - Dow, Edward
AU  - Jobanputra, Nishith
AU  - Esseltine, Dixie-Lee
AU  - Niculescu, Liviu
AU  - Anderson, Kenneth C.
AU  - Lonial, Sagar
AU  - Richardson, Paul G.
PY  - 2017
SN  - 0007-1048
UR  - http://hdl.handle.net/10366/146204
AB  - [EN] This retrospective analysis aimed to establish the overall cardiac safety profile of bortezomib using patient-level data from one phase 2 and seven phase 3 studies in previously untreated and relapsed/refractory multiple myeloma (MM). Seven...
LA  - eng
PB  - British Journal of Haematology
KW  - Cardiac
KW  - Bortezomib
KW  - Cardio-oncology
KW  - Multiple myeloma
KW  - Medical Oncology
KW  - Multiple Myeloma
TI  - A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma
DO  - 10.1111/bjh.14708
T2  - British Journal of Haematology
VL  - 178
M2  - 547
ER  -